BB was created to create Dharmanol. Highlights from Hoye's extraordinary essay:
"Berkeley Bio was created with the intention of developing a non-psychoactive treatment for cancer..."
"Earlier this year, Berkeley Bio was acquired by SK3 Group. This move provided the funding and resources that Berkeley Bio needed to successfully complete its current work, medicinalization of the phytocannabinoids into a powerful cannabinoid medicine, without the overwhelming psychoactive side effects of THC.
THC is the psychoactive cannabinoid found in marijuana. The higher the levels of THC, the stronger and more intense the high. But THC is only one of the 80 or so different related molecules that are called cannabinoids. CBD is a “chemical cousin” to THC, and exhibits many of the same anti-tumor and anti-cancer properties. CBD is non-psychoactive; a patient can take large doses with minimal side effects.
There has been a great deal of research done on CBD because researchers believed that funding and approval would be easier with CBD than the psychoactive THC. Numerous laboratory experiments have shown that CBD is likely as effective as THC in many but not all cases.
CBD is an important part of Dharmanol™ a new natural medicine recently developed by Berkeley Bio. Along with CBD, Dharmanol™ contains a wide array of natural cannabinoids that have been extracted from hemp/cannabis and preserved in their non-psychoactive form utilizing a proprietary technology developed by Gold and Apel.
The use of cannabinoids in their non-psychoactive “carboxylate” form was pioneered by Dr. William Courtney of Willits, California. Along with being an MD with a thriving practice, Dr. Courtney is the founder of the Cannabis International Foundation.
For a number of years, Dr. Courtney has been treating patients with huge doses of cannabis juice. He has seen outstanding results that he has described on several YouTube videos.
The drawback to Dr. Courtney’s therapy is that it requires the patient to maintain 40 to 80 live growing marijuana plants in order to have a daily dose of juice. While perhaps not as effective as the fresh, green, living, juice that is consumed with Dr. Courtney’s method, the carboxylates present in Dharmanol™ go a long way towards providing the same benefits without the extreme difficulty of maintaining live marijuana plants.
Along with the CBD and mixed cannabinoid carboxylates, the third component of Dharmanol™ is a steam-distilled extract of a variety of strains of cannabis. This preparation contains the terpenes and terpenoids found in marijuana, many of which have been shown to have substantial medicinal value in themselves, as well as potentiating the activity of some of the cannabinoids.
Berkeley Bio developed Dharmanol™ to contain as much of the wide spectrum of medicinally active elements of the plant as possible. This is known in the world of medicinal cannabis as “whole plant” therapy, and most perceive a wide array of the cannabis medicinals to be far more effective than single isolated elements of the cannabis plant, whether extracted or synthesized.
The Dharma Care and Hospice Program has been supplying patients with a whole-plant preparation in capsule form for many years. Formulated to contain as many elements of the raw plant as possible, many patients in California have found that whole-plant therapy is superior to any purified and isolated compounds. Dharmanol™ has been designed to provide the widest spectrum of beneficial compounds of the cannabis plant, in their non-psychoactive form, just as the aforementioned capsules provided the widest healing array possible, but included the psychoactive THC.
Dharmanol™ has been designed to treat any of the myriad of conditions for which physicians are now recommending that patients try cannabinoid medicine. Modern research tells us that this includes treatments for a great number of different conditions.
The main focus of Berkeley Bio has been the development of medicines for the prevention and treatment of cancer. Dharmanol™, in both low-dose and high-dose forms, may prove to be an effective medicine in both prevention and treatment.
Low-dose tablets contain 5mg. CBD, 5 mg. mixed cannabinoid carboxylates, and 5 mg. of steam-distilled terpenes and terpenoids. A daily supplement such as this will gently stimulate the endo-cannabinoid system, which regulates and enhances many of the body’s own health-promoting processes, such as the immune system. These are the systems that keep cancer and other opportunistic diseases in check in otherwise-healthy individuals.
High-dose Dharmanol™ therapy is designed to provide the same effects as Simpson oil therapy without the psychoactive side effects. While neither Dr. Courtney’s juicing therapy, or treatment with non-psychoactive CBD has had near the amount of “anecdotal” study as Simpson’s therapy with standard cannabis oil, the scientific studies on CBD, and the anecdotal evidence of the numerous patients treated with Dr. Courtney’s carboxylates, indicates that high-dose Dharmanol™ therapy should be every bit as effective as Simpson oil, but without the physical, mental, and emotional side effects.
Two additional benefits are present with Dharmanol™ that are not to be found with standard Simpson therapy. The removal of the psychoactivity allows patients who cannot tolerate Simpson oil to treat their conditions with adequate amounts of cannabinoids, and the removal of the psychoactivity allows patients to tolerate much larger doses.
The capacity to increase the dosage by removing the psychoactivity holds much promise. The “standard” Simpson dose is well under one one-thousandth of the dose of cannabinoids said to be capable of causing physical harm to the organism. The reason that one gram is the dose recommended by Simpson is that few people could possibly tolerate more than this.
With the amazing anecdotal results surrounding Simpson oil, combined with the fact that many of cannabis’ mechanisms are dose-dependent, it stands to reason that increasing the daily dose of cannabinoids ten, or perhaps one hundred times, could provide a medicine that no cancer could possibly stand up against. Hopefully, clinical trials of Dharmanol™ will show whether this is so.
David Hoye is the Research Director, Berkeley Bio-Organic Research Laboratories. He works in conjunction with Dr. Charles Apel, who is Chief Science Office
"Berkeley Bio was created with the intention of developing a non-psychoactive treatment for cancer..."
"Earlier this year, Berkeley Bio was acquired by SK3 Group. This move provided the funding and resources that Berkeley Bio needed to successfully complete its current work, medicinalization of the phytocannabinoids into a powerful cannabinoid medicine, without the overwhelming psychoactive side effects of THC.
THC is the psychoactive cannabinoid found in marijuana. The higher the levels of THC, the stronger and more intense the high. But THC is only one of the 80 or so different related molecules that are called cannabinoids. CBD is a “chemical cousin” to THC, and exhibits many of the same anti-tumor and anti-cancer properties. CBD is non-psychoactive; a patient can take large doses with minimal side effects.
There has been a great deal of research done on CBD because researchers believed that funding and approval would be easier with CBD than the psychoactive THC. Numerous laboratory experiments have shown that CBD is likely as effective as THC in many but not all cases.
CBD is an important part of Dharmanol™ a new natural medicine recently developed by Berkeley Bio. Along with CBD, Dharmanol™ contains a wide array of natural cannabinoids that have been extracted from hemp/cannabis and preserved in their non-psychoactive form utilizing a proprietary technology developed by Gold and Apel.
The use of cannabinoids in their non-psychoactive “carboxylate” form was pioneered by Dr. William Courtney of Willits, California. Along with being an MD with a thriving practice, Dr. Courtney is the founder of the Cannabis International Foundation.
For a number of years, Dr. Courtney has been treating patients with huge doses of cannabis juice. He has seen outstanding results that he has described on several YouTube videos.
The drawback to Dr. Courtney’s therapy is that it requires the patient to maintain 40 to 80 live growing marijuana plants in order to have a daily dose of juice. While perhaps not as effective as the fresh, green, living, juice that is consumed with Dr. Courtney’s method, the carboxylates present in Dharmanol™ go a long way towards providing the same benefits without the extreme difficulty of maintaining live marijuana plants.
Along with the CBD and mixed cannabinoid carboxylates, the third component of Dharmanol™ is a steam-distilled extract of a variety of strains of cannabis. This preparation contains the terpenes and terpenoids found in marijuana, many of which have been shown to have substantial medicinal value in themselves, as well as potentiating the activity of some of the cannabinoids.
Berkeley Bio developed Dharmanol™ to contain as much of the wide spectrum of medicinally active elements of the plant as possible. This is known in the world of medicinal cannabis as “whole plant” therapy, and most perceive a wide array of the cannabis medicinals to be far more effective than single isolated elements of the cannabis plant, whether extracted or synthesized.
The Dharma Care and Hospice Program has been supplying patients with a whole-plant preparation in capsule form for many years. Formulated to contain as many elements of the raw plant as possible, many patients in California have found that whole-plant therapy is superior to any purified and isolated compounds. Dharmanol™ has been designed to provide the widest spectrum of beneficial compounds of the cannabis plant, in their non-psychoactive form, just as the aforementioned capsules provided the widest healing array possible, but included the psychoactive THC.
Dharmanol™ has been designed to treat any of the myriad of conditions for which physicians are now recommending that patients try cannabinoid medicine. Modern research tells us that this includes treatments for a great number of different conditions.
The main focus of Berkeley Bio has been the development of medicines for the prevention and treatment of cancer. Dharmanol™, in both low-dose and high-dose forms, may prove to be an effective medicine in both prevention and treatment.
Low-dose tablets contain 5mg. CBD, 5 mg. mixed cannabinoid carboxylates, and 5 mg. of steam-distilled terpenes and terpenoids. A daily supplement such as this will gently stimulate the endo-cannabinoid system, which regulates and enhances many of the body’s own health-promoting processes, such as the immune system. These are the systems that keep cancer and other opportunistic diseases in check in otherwise-healthy individuals.
High-dose Dharmanol™ therapy is designed to provide the same effects as Simpson oil therapy without the psychoactive side effects. While neither Dr. Courtney’s juicing therapy, or treatment with non-psychoactive CBD has had near the amount of “anecdotal” study as Simpson’s therapy with standard cannabis oil, the scientific studies on CBD, and the anecdotal evidence of the numerous patients treated with Dr. Courtney’s carboxylates, indicates that high-dose Dharmanol™ therapy should be every bit as effective as Simpson oil, but without the physical, mental, and emotional side effects.
Two additional benefits are present with Dharmanol™ that are not to be found with standard Simpson therapy. The removal of the psychoactivity allows patients who cannot tolerate Simpson oil to treat their conditions with adequate amounts of cannabinoids, and the removal of the psychoactivity allows patients to tolerate much larger doses.
The capacity to increase the dosage by removing the psychoactivity holds much promise. The “standard” Simpson dose is well under one one-thousandth of the dose of cannabinoids said to be capable of causing physical harm to the organism. The reason that one gram is the dose recommended by Simpson is that few people could possibly tolerate more than this.
With the amazing anecdotal results surrounding Simpson oil, combined with the fact that many of cannabis’ mechanisms are dose-dependent, it stands to reason that increasing the daily dose of cannabinoids ten, or perhaps one hundred times, could provide a medicine that no cancer could possibly stand up against. Hopefully, clinical trials of Dharmanol™ will show whether this is so.
David Hoye is the Research Director, Berkeley Bio-Organic Research Laboratories. He works in conjunction with Dr. Charles Apel, who is Chief Science Office
